Medipure Holdings Inc. Announces Publication of U.S. and International PCT Patent Application for MP20X, a Drug Formulation to Treat Anxiety and Depression

Vancouver, BC – September # 2020 – Medipure Holdings Inc. (“Medipure” or the “Company”), is pleased to announce the publication of U.S. patent applications 20200253947 and 20200253948 and the publication international PCT patent application (PCT/CA2020/050165) for MP20X. The published patents relate to pharmaceutical formulations for treating anxiety and depression, specifically, formulations that combine one or more than one cannabinoid receptor agonist and one or more than one serine hydrolase enzyme inhibitor as anxiolytic therapeutic product.

 

“We are very pleased to formally announce the publication of our MP20X patent application with both the USPTO and International PCT”, stated Boris Weiss, Medipure’s Chief Executive Officer. “MP20X is an exciting addition to our portfolio of intellectual property and serves to highlight the considerable potential of our research and development efforts”.  Dr. Nihar Pandey, Medipure’s Chief Scientific Officer, added that “the global market for anxiety and related mood disorder medication is one of the larger growing therapeutic segments of the pharmaceutical industry.  Many available first line medications are associated with severe dependency issues and often considered as a substance of drug abuse. Our endocannabinoid-targeted prescription medications are intended to create safe and effective alternatives that either mitigate or eliminate these challenges. I am excited to continue moving MP-20X towards production, and to the benefits it may provide for both patients and doctors.”

 

The publication of the patent application is the last step before a full patent can be granted by either the USPTO or International PCT.

 

About Medipure

 

Medipure is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms.

 

Cautionary Note Regarding Forward Looking Information

 

This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward- looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, failure to be granted a full patent, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

 

For further information: Boris Weiss, Chief Executive Officer and President Boris@medipurepharma.com